Bymaa Laboratories Profile
Key Indicators
- Authorised Capital ₹ 7.25 Cr
as on 31-08-2024
- Paid Up Capital ₹ 7.23 Cr
as on 31-08-2024
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.80 Cr
as on 31-08-2024
- Satisfied Charges ₹ 9.07 Cr
as on 31-08-2024
- Revenue 71.62%
(FY 2023)
- Profit 112.26%
(FY 2023)
- Ebitda 5178.86%
(FY 2023)
- Net Worth 1.54%
(FY 2023)
- Total Assets 8.94%
(FY 2023)
About Bymaa Laboratories
The Corporate was formerly known as Lexand Research Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.25 Cr and a paid-up capital of Rs 7.23 Cr.
The company currently has active open charges totaling ₹4.80 Cr. The company has closed loans amounting to ₹9.07 Cr, as per Ministry of Corporate Affairs (MCA) records.
Chinnaiyan Raja, Abdul Moin, Mohammed Zubair, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231PY2006PTC002010
- Company No.
002010
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2006
- Date of AGM
21 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Villupuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bymaa Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chinnaiyan Raja  | Whole-Time Director | 27-Apr-2017 | Current |
| Abdul Moin | Director | 23-Feb-2015 | Current |
| Mohammed Zubair | Director | 14-May-2015 | Current |
| Veera Dharshini | Director | 18-Aug-2021 | Current |
Financial Performance of Bymaa Laboratories.
Bymaa Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 71.62% increase. The company also saw a substantial improvement in profitability, with a 112.26% increase in profit. The company's net worth moved up by a moderate rise of 1.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bymaa Laboratories?
In 2023, Bymaa Laboratories had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 20 Jul 2024 | ₹2.30 Cr | Open |
Indian Overseas Bank Creation Date: 15 Dec 2022 | ₹2.50 Cr | Open |
Indian Oversas Bank Creation Date: 29 Oct 2007 | ₹9.07 Cr | Satisfied |
How Many Employees Work at Bymaa Laboratories?
Bymaa Laboratories has a workforce of 57 employees as of Aug 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bymaa Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bymaa Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
